BEUDAMED
    FDA Adverse Event Malfunction Summary report: N

    LUMIRADX SARS-COV-2 AG TEST STRIP KIT

    MDR report key: 11837893 · Received May 17, 2021

    Report

    Report Number
    3012642695-2021-01103
    Event Type
    Malfunction
    Date Received
    May 17, 2021
    Date of Event
    April 18, 2021
    Report Date
    May 17, 2021
    Manufacturer
    LUMIRADX UK LTD.
    Product Code
    QKP
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    US
    Reporter Occupation
    OTHER

    Narratives

    Additional Manufacturer Narrative · 1

    PATIENT WAS REPORTED TO BE SYMPTOMATIC WHEN INITIAL LUMIRADX SARS-COV-2 AG TEST WAS PERFORMED ON (B)(6) 2021 WITH STRIP LOT 6000147 AND INSTRUMENT SERIAL NUMBER (B)(4). NEITHER SECONDARY NOR CONFIRMATORY POLYMERASE CHAIN REACTION (PCR) TESTING WAS REPORTED TO HAVE BEEN PERFORMED. SAMPLING FOR INITIAL LUMIRADX SARS-COV-2 AG WAS SELF-COLLECTED BY THE PATIENT. THE CUSTOMER REPORTED THE FOLLOWING PROCESS FOR TESTING ON THE LUMIRADX PLATFORM: "ONE PATIENT PROCESSED AT A TIME. PATIENT SELF COLLECTS SWAB AND HANDS TO NURSE TO PLACE IN EXTRACTION VIAL. THAT EXTRACTION VIAL IS PROCESSED AND TESTING PERFORMED IMMEDIATELY. ONLY ONE PATIENT IN THE KIOSK AT A TIME." THE CUSTOMER REPORTED THEIR CLEANING PRACTICES TO BE: "CLEAN WITH PDI SANI-CLOTH BLEACH WIPES BETWEEN EACH PATIENT. REPLACE PAPER BARRIER BETWEEN ALL POSITIVE SAMPLES AS WELL", AND FURTHER REPORTED THAT GLOVES ARE CHANGED AFTER EACH SAMPLE. LOT 6000147 MET ALL DEFINED QC CRITERIA AT THE TIME IT WAS RELEASED AND TESTING USING NEGATIVE NASAL SWABS FROM IN-HOUSE DONORS MEETS EXPECTED PERFORMANCE FOR USE IN THE FIELD. REVIEW OF PRODUCT RISK ASSESSMENT - SARS-COV-2 AG ASSAY REVISION 7, RESULTED IN SEVERITY OF MODERATE, AS FOLLOWS: DELAYED DIAGNOSIS LEADING TO DELAYED TREATMENT OF THE TRUE CAUSE OF THE PATIENT'S SYMPTOMS. UNNECESSARY ISOLATION. NO PATIENT HARM, INJURY OR ADVERSE HEALTH CONSEQUENCES WERE COMMUNICATED BY THE CUSTOMER TO LUMIRADX FOR THE REPORTED DISCORDANT RESULT. TRENDING DATA FOR DISCORDANT RESULTS WAS REVIEWED FOR THIS LOT AND THE OCCURRENCE RATE PER QUANTITY OF STRIPS IN THE FIELD WAS CALCULATED AS (B)(4). LUMIRADX SARS-COV-2 AG TEST PRODUCT INSERT CLAIMS A SPECIFICITY OF 96.6% WITH A REFERENCE RT-PCR ASSAY AND IT IS ACCEPTED THAT UP TO 3.4% OF TEST STRIPS MAY GENERATE A DISCORDANT FALSE POSITIVE RESULT. ROOT CAUSE DETERMINATION: NO DEFINITIVE ROOT CAUSE HAS BEEN DETERMINED FOR THE REPORTED DISCORDANT RESULT BASED ON THE INFORMATION CURRENTLY AVAILABLE. INVESTIGATION CONCLUSION AND STATUS OF INVESTIGATION: NO FURTHER INVESTIGATION IS CONSIDERED NECESSARY AT THIS TIME. THIS STRIP LOT CONTINUES TO DEMONSTRATE FIELD PERFORMANCE WITHIN SPECIFICATION OF PRODUCT CLAIMS RELATIVE TO THE QUANTITY OF STRIPS FROM THIS LOT IN THE FIELD. REPORTS OF DISCORDANT RESULTS FOR THIS LOT WILL CONTINUE TO BE TRENDED AND REVIEWED, WITH ACTION TAKEN AS APPROPRIATE IN RESPONSE TO ANY ADVERSE TRENDS OR EVENTS INCLUDING A FOLLOW-UP REPORT.

    Description of Event or Problem · 1

    THE PATIENT'S FATHER REPORTED A SUSPECTED FALSE (INCORRECT) POSITIVE RESULT FROM A RAPID RESULT COVID TEST SYSTEM ON AN INDIVIDUAL SYMPTOMATIC PATIENT.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    733936 LUMIRADX SARS-COV-2 AG TEST STRIP KIT CORONAVIRUS ANTIGEN DETECTION TEST SYSTEM QKP LUMIRADX UK LTD. 6000147

    Patients

    Seq Age Sex Outcome Treatment
    1